ArticleTranslational cancer research2022
A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- COL11A1 promotes lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a COL11A1-related prognostic signature.Frontiers in oncology · 2026Article
- Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.BMC cancer · 2025Article
- Exploring the tumor microenvironment of breast cancer to develop a prognostic model and predict immunotherapy responses.Scientific reports · 2025Article
- LncRNA-associated ceRNA Network Revealing the Potential Regulatory Roles of Ferroptosis and Immune Infiltration in Osteosarcoma as well as Construction of the Prognostic Model.Current medicinal chemistry · 2025Article
- Development of a prognostic model for NSCLC based on differential genes in tumour stem cells.Scientific reports · 2024Article
- Article
- Comprehensive analysis identifies DNA damage repair-related gene HCLS1 associated with good prognosis in lung adenocarcinoma.Translational cancer research · 2023Article
- Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.Functional & integrative genomics · 2023Article
- Development and validation of a novel M1 macrophage-related gene prognostic signature for lung cancer.Journal of thoracic disease · 2023Article
- Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.BMC bioinformatics · 2023Article
- Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.Oncology research · 2023Article
- Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer.Frontiers in endocrinology · 2023Article
- Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.American journal of cancer research · 2023Article
- A novel neutrophil extracellular traps-related lncRNA signature predicts prognosis in patients with early-stage lung adenocarcinoma.Annals of medicine · 2023Article
- A novel prognostic signature for lung adenocarcinoma based on cuproptosis-related lncRNAs: A Review.Medicine · 2022Review
- A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies.Journal of clinical laboratory analysis · 2022Article
- The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma.Respiratory research · 2022Article
- Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.Scientific reports · 2022Article
- A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autophagy inhibits tumorigenesis by limiting inflammation. Various lncRNAs are associated with tumour biological processes, including lung adenocarcinoma (LUAD), but the role of autophagy-related lncRNAs (ARlncRNAs) in LUAD has not been fully elucidated. Thus, this study aimed to construct a prognostic signature based on ARlncRNAs for LUAD. Methods: The RNA-seq (FPKM) data and clinical information of LUAD patients were downloaded from The Cancer Genome Atlas (TCGA) database. After differentially expressed lncRNAs in tumour and normal groups were identified, cox regression analyses were performed to construct a prognostic signature which was then assessed through independent prognostic analysis and functional enrichment analysis. Moreover, based on the mRNAs co-expressed with the ARlncRNAs, several potential small molecule drugs were explored in the Connectivity map (Cmap). Results: A signature consisting of seven ARlncRNAs (FAM83A-AS1, LINC01116, ILF3-DT, EBLN3P, AL161785.1, AC092279.1 and AC026355.2) was constructed to predict overall survival (OS) for LUAD. The signature was identified to be independent by the cox regression analysis and obtained the largest area under the curve (AUC =0.721) in the receiver operating characteristic (ROC). Six small molecule drugs (MS-275, methotrexate, desipramine, benzbromarone, rifampicin and doxazosin) were selected from Cmap. Conclusions: A novel ARlncRNA signature for LUAD prognostic prediction was constructed, which had better efficacy than the TNM stage and used to propose potential therapeutic regimens for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.